Indomethacin: Difference between revisions
Elcatracho (talk | contribs) |
|||
| (23 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[NSAID]] | ||
*Dosage Forms: | *Dosage Forms: PO (Generic in 25 and 50mg tabs) | ||
*Common Trade Names: | *Common Trade Names: Indocin | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 8: | Line 8: | ||
*50-100mg loading dose, 25mg q4-6 hrs for 48 hrs | *50-100mg loading dose, 25mg q4-6 hrs for 48 hrs | ||
Osteoarthritis: | [[Osteoarthritis]]: | ||
* | *25mg PO BID-TID, max 200mg/day, give with food | ||
[ | [[Gout and Pseudogout]]: | ||
* | *50mg PO TID, taper dose rapidly | ||
Ankylosing Spondylitis: | [[Ankylosing Spondylitis]]: | ||
* | *25mg PO bid-tid, max 200mg/day | ||
[ | [[Rheumatoid Arthritis]]: | ||
* | *25mg PO bid-tid, max 200mg/day | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Patent | [[Patent ductus arteriosus]]: | ||
* <48 hour old: start 0. | *<48 hour old: start 0.2mg/kg IV x 1, then 0.1mg/kg q12-24h x 2 | ||
* 2-7 days old: Start 0. | *2-7 days old: Start 0.2mg/kg IV x 1, then 0.2mg/kg q12-24h x 2 | ||
* > 7 days old: Start 0. | *> 7 days old: Start 0.2mg/kg IV x 1, then 0.25mg/kg q12-24h x 2 | ||
[[Rheumatoid_arthritis|Rheumatoid Arthritis]] | [[Rheumatoid_arthritis|Rheumatoid Arthritis]] | ||
* 1- | *1-2mg/kg/day PO divided BID-QID, max 4mg/kg/day up to 150-200mg/day | ||
==Special Populations== | ==Special Populations== | ||
| Line 42: | Line 42: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*ASA or NSAID-induced ashtma or urticaria | |||
*Pregnancy 3rd trimester | |||
*Infection, untreated (neonates) | |||
*Active bleeding (neonates) | |||
*Thrombocytopenia (neonates) | |||
*Coagulation Disorder (neonates) | |||
*Necrotizing enterocolitis (neonates) | |||
*renal impairment, significant (neonates) | |||
*Pulmonary atresia (neonates) | |||
*Tetralogy of Fallot, severe (neonates) | |||
*Aortic coarctation, severe (neonates) | |||
*CABG surgery period use | |||
*caution if cardiovascular disease | |||
*caution if hypertension | |||
*caution if CHF | |||
*caution if fluid retention | |||
*caution if GI bleeding or ulcer history | |||
*caution in elderly patients | |||
*caution if dehydration | |||
*caution if sepsis | |||
*caution if asthma | |||
*caution if prolonged use | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*pulmonary hemorrhage (neonates) | |||
*[[GI bleeding]] | |||
*GI perforation/ulcer | |||
*[[MI]] | |||
*Stroke | |||
*Thromboembolism | |||
*hypertension | |||
*[[CHF]] | |||
*Renal Papillary Necrosis | |||
*[[Acute Renal Failure]] | |||
*Hepatotoxicity | |||
*[[Steven_Johnson_syndrome|Steven-Johnson syndrome]] | |||
*Anemia | |||
*[[Thrombocytopenia|Thrombocytopenia, neonates]] | |||
*hyponatremia (neonates) | |||
*hyperkalemia (neonates) | |||
===Common=== | ===Common=== | ||
*dyspepsia | |||
*nausea | |||
*abdominal pain | |||
*constipation | |||
*headache | |||
*dizziness | |||
*rash | |||
*ALT,AST elevation | |||
*fluid retention | |||
*tinnitus | |||
*corneal deposits | |||
*photosensitivity | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 4.5 hours, 12-21 hours in neonates | ||
*Metabolism: | *Metabolism: Liver; CYP450, 2C9 substrate | ||
*Excretion: | *Excretion: urine 60%, feces 33% | ||
*Mechanism of Action: | *Mechanism of Action: exact mechanism unknown, inhibits cyclooxygenase, reducing prostaglandin and thromboxane synthesis | ||
==See Also== | ==See Also== | ||
*[[NSAID toxicity]] | |||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category: | |||
Latest revision as of 22:40, 7 March 2021
General
- Type: NSAID
- Dosage Forms: PO (Generic in 25 and 50mg tabs)
- Common Trade Names: Indocin
Adult Dosing
Preterm labor/Tocolysis
- 50-100mg loading dose, 25mg q4-6 hrs for 48 hrs
- 25mg PO BID-TID, max 200mg/day, give with food
- 50mg PO TID, taper dose rapidly
- 25mg PO bid-tid, max 200mg/day
- 25mg PO bid-tid, max 200mg/day
Pediatric Dosing
- <48 hour old: start 0.2mg/kg IV x 1, then 0.1mg/kg q12-24h x 2
- 2-7 days old: Start 0.2mg/kg IV x 1, then 0.2mg/kg q12-24h x 2
- > 7 days old: Start 0.2mg/kg IV x 1, then 0.25mg/kg q12-24h x 2
- 1-2mg/kg/day PO divided BID-QID, max 4mg/kg/day up to 150-200mg/day
Special Populations
- Pregnancy Rating: B
- Lactation: probably safe
- Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
- Hepatic Dosing
- Adult: not defined, caution advised if hepatic impairment
- Pediatric: not defined, caution advised if hepatic impairment
Contraindications
- Allergy to class/drug
- ASA or NSAID-induced ashtma or urticaria
- Pregnancy 3rd trimester
- Infection, untreated (neonates)
- Active bleeding (neonates)
- Thrombocytopenia (neonates)
- Coagulation Disorder (neonates)
- Necrotizing enterocolitis (neonates)
- renal impairment, significant (neonates)
- Pulmonary atresia (neonates)
- Tetralogy of Fallot, severe (neonates)
- Aortic coarctation, severe (neonates)
- CABG surgery period use
- caution if cardiovascular disease
- caution if hypertension
- caution if CHF
- caution if fluid retention
- caution if GI bleeding or ulcer history
- caution in elderly patients
- caution if dehydration
- caution if sepsis
- caution if asthma
- caution if prolonged use
Adverse Reactions
Serious
- pulmonary hemorrhage (neonates)
- GI bleeding
- GI perforation/ulcer
- MI
- Stroke
- Thromboembolism
- hypertension
- CHF
- Renal Papillary Necrosis
- Acute Renal Failure
- Hepatotoxicity
- Steven-Johnson syndrome
- Anemia
- Thrombocytopenia, neonates
- hyponatremia (neonates)
- hyperkalemia (neonates)
Common
- dyspepsia
- nausea
- abdominal pain
- constipation
- headache
- dizziness
- rash
- ALT,AST elevation
- fluid retention
- tinnitus
- corneal deposits
- photosensitivity
Pharmacology
- Half-life: 4.5 hours, 12-21 hours in neonates
- Metabolism: Liver; CYP450, 2C9 substrate
- Excretion: urine 60%, feces 33%
- Mechanism of Action: exact mechanism unknown, inhibits cyclooxygenase, reducing prostaglandin and thromboxane synthesis
